PMID- 19615725
OWN - NLM
STAT- MEDLINE
DCOM- 20090907
LR  - 20180720
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 115
IP  - 1
DP  - 2009 Oct
TI  - Primary fallopian tube carcinoma: results of a retrospective analysis of 64 
      patients.
PG  - 97-101
LID - S0090-8258(09)00474-0 [pii]
LID - 10.1016/j.ygyno.2009.06.025 [doi]
AB  - OBJECTIVE: The objective of this retrospective study was to determine the 
      clinical outcomes of patients with primary fallopian tube carcinoma (PFTC) 
      treated with paclitaxel and platinum analogue-based combination chemotherapy 
      following primary cytoreductive surgery. METHODS: Sixty-four patients with the 
      diagnosis of PFTC were identified through the gynecology service database and the 
      tumor registry of 4 different institutions. The majority of patients (48/64, 75%) 
      were treated with carboplatin AUC (area under curve) 6 and paclitaxel 175 mg/m(2) 
      as a 3 h infusion. RESULTS: Among 28 patients with measurable disease, we 
      observed 19 (68%) complete clinical and 7 (25%) partial responses for an overall 
      response rate of 93%. After a median follow-up of 40 months (3+-134+ months), the 
      5-year survival rate of the entire population was 70% (median overall survival 
      [mOS] not reached) and the median time to tumor progression (mTTP) was 81 months 
      (95% CI: 53-109). Stage and residual disease were of prognostic significance. The 
      mTTP was not reached in patients with stage I/II and was 38 months for patients 
      with stage III/IV (p=0.004). The mOS for patients with stage I/II was not 
      reached, whereas it was 62 months for those with stage III/IV (p=0.057). The mTTP 
      was 86 and 23 months for patients with residual disease <2 cm and >2 cm, 
      respectively (p<0.001). The mOS was not reached for patients with residual 
      disease <2 cm, while it was 36 months for residual disease >2 cm (p<0.001). 
      CONCLUSION: Optimally cytoreduced patients with PFTC treated with platinum and 
      paclitaxel-based chemotherapy regimen have an excellent possibility of survival.
FAU - Pectasides, D
AU  - Pectasides D
AD  - 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University 
      of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece.
FAU - Pectasides, E
AU  - Pectasides E
AD  - 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University 
      of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece. 
      Electronic address: pectasid@otenet.gr.
FAU - Papaxoinis, G
AU  - Papaxoinis G
AD  - 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University 
      of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece.
FAU - Andreadis, C
AU  - Andreadis C
AD  - Department of Medical Oncology, Theagenion Cancer Hospital, Thessaloniki, Greece.
FAU - Papatsibas, G
AU  - Papatsibas G
AD  - 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University 
      of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece.
FAU - Fountzilas, G
AU  - Fountzilas G
AD  - Department of Medical Oncology, "Papageorgiou" Hospital, Aristotle University of 
      Thessaloniki School of Medicine, Thessaloniki, Greece.
FAU - Pliarchopoulou, K
AU  - Pliarchopoulou K
AD  - 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University 
      of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece.
FAU - Macheras, A
AU  - Macheras A
AD  - 3rd Department of Surgery, University of Athens, "Attikon" University Hospital, 
      Haidari, 1 Rimini, Athens, Greece.
FAU - Aravantinos, G
AU  - Aravantinos G
AD  - 3rd Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, 
      Greece.
FAU - Economopoulos, T
AU  - Economopoulos T
AD  - 2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University 
      of Athens, "Attikon" University Hospital, Haidari, 1 Rimini, Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20090716
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Cisplatin/administration & dosage
MH  - Cyclophosphamide/administration & dosage
MH  - Disease-Free Survival
MH  - Doxorubicin/administration & dosage
MH  - Fallopian Tube Neoplasms/*drug therapy/pathology/*surgery
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Paclitaxel/administration & dosage
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2009/07/21 09:00
MHDA- 2009/09/08 06:00
CRDT- 2009/07/21 09:00
PHST- 2009/05/21 00:00 [received]
PHST- 2009/06/14 00:00 [revised]
PHST- 2009/06/17 00:00 [accepted]
PHST- 2009/07/21 09:00 [entrez]
PHST- 2009/07/21 09:00 [pubmed]
PHST- 2009/09/08 06:00 [medline]
AID - S0090-8258(09)00474-0 [pii]
AID - 10.1016/j.ygyno.2009.06.025 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2009 Oct;115(1):97-101. doi: 10.1016/j.ygyno.2009.06.025. Epub 
      2009 Jul 16.